Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ENDRA Life Sciences Inc

NDRA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$4.47

▲ +0.00%

Market Cap $9.52M · Vol 9.09K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$9.52M

Micro Cap

Div Yield

N/A

EPS Growth

+60.36%

YoY

RSI (14)

42.29

Momentum

Beta

-0.03

vs Market

52W High

$9.83

54.53% below

52W Low

$2.96

51.01% above

Volume

9.09K

Avg 5.75K

P/B

2.36

Price-to-book

ROE

N/A

Return on equity

Free Float

85.82%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, ENDRA Life Sciences Inc (NDRA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NDRA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.89%

-19.31%

-24.24%

+25.92%

YTD

-1.32%

+0.68%

-99.78%

-99.99%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-7,027,410.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-169.21% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.36
P/FCF	N/A
EPS Growth	+60.36%
Outstanding Shares	2.13M

Technical Indicators

50-Day SMA	$4.84
200-Day SMA	$4.80
RSI (14)	42.29
Beta	-0.03
52-Week High	$9.83
52-Week Low	$2.96

Volume Today	9.09K
Avg Daily Volume (30D)	5.75K
Relative Volume	1.58x
Volatility (10D)	73.29
Volatility (30D)	83.92
Free Float	85.82%

Analyst Consensus

BUY

Current Price $4.47

Mean Target $25.00

52W Low$2.96 52W High$9.83

Current

Target

$2.96 $9.83

Current Analyst target

+459.28% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00FD4RDM1

ISINUS29273B5003

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateAug 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.